TW240171B - - Google Patents

Info

Publication number
TW240171B
TW240171B TW082108050A TW82108050A TW240171B TW 240171 B TW240171 B TW 240171B TW 082108050 A TW082108050 A TW 082108050A TW 82108050 A TW82108050 A TW 82108050A TW 240171 B TW240171 B TW 240171B
Authority
TW
Taiwan
Application number
TW082108050A
Other languages
Chinese (zh)
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Application granted granted Critical
Publication of TW240171B publication Critical patent/TW240171B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW082108050A 1992-12-17 1993-10-01 TW240171B (enEXAMPLES)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/991,909 US5326552A (en) 1992-12-17 1992-12-17 Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants

Publications (1)

Publication Number Publication Date
TW240171B true TW240171B (enEXAMPLES) 1995-02-11

Family

ID=25537712

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082108050A TW240171B (enEXAMPLES) 1992-12-17 1993-10-01

Country Status (17)

Country Link
US (2) US5326552A (enEXAMPLES)
EP (1) EP0602700A3 (enEXAMPLES)
JP (1) JPH06192131A (enEXAMPLES)
KR (1) KR940013544A (enEXAMPLES)
AU (1) AU664115B2 (enEXAMPLES)
CA (1) CA2107165A1 (enEXAMPLES)
CZ (1) CZ266893A3 (enEXAMPLES)
FI (1) FI935396L (enEXAMPLES)
HU (1) HUT67265A (enEXAMPLES)
IL (1) IL107875A0 (enEXAMPLES)
MX (1) MX9306012A (enEXAMPLES)
MY (1) MY109875A (enEXAMPLES)
NO (1) NO934425L (enEXAMPLES)
NZ (1) NZ248727A (enEXAMPLES)
PH (1) PH30158A (enEXAMPLES)
SK (1) SK142793A3 (enEXAMPLES)
TW (1) TW240171B (enEXAMPLES)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5525327A (en) * 1994-04-14 1996-06-11 Sterling Winthrop Inc. Polymeric x-ray contrast compositions containing iodinated polymeric beads and microcrystaline cellulose
US5368837A (en) * 1994-04-14 1994-11-29 Sterling Winthrop Inc. X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative
US6645463B1 (en) 1994-05-16 2003-11-11 The Board Of Regents Of The University Of Michigan Blood-pool selective carrier for lipophilic imaging agents
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
ATE274341T1 (de) * 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
US5962380A (en) * 1995-06-06 1999-10-05 Chevron Chemical Company Llc Fluorocarbon elastomer compatibility improving agent having wear inhibition effect
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
AU743917B2 (en) * 1996-08-22 2002-02-07 Rtp Pharma Corporation Compositions comprising microparticles of water-insoluble substances
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
EP0925061B1 (en) * 1996-08-22 2005-12-28 Jagotec Ag Compositions comprising microparticles of water-insoluble substances and method for preparing same
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
GB9705340D0 (en) * 1997-03-14 1997-04-30 Nycomed Imaging As Compositions
WO1998048847A1 (en) * 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
GB9712981D0 (en) * 1997-06-19 1997-08-27 Nycomed Imaging As Compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
ES2257041T3 (es) 1998-03-30 2006-07-16 Jagotec Ag Composicion y metodo para preparar microparticulas de substancias insolubles en agua.
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
HK1039458B (zh) 1998-05-29 2006-09-01 Skyepharma Canada Inc. 熱保護微粒組合物及其最終蒸汽滅菌的方法
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
PL201578B1 (pl) 1998-11-20 2009-04-30 Skyepharma Canada Inc Stała terapeutyczna postać dawkowania nierozpuszczalnego lub słabo rozpuszczalnego w wodzie związku
US6309596B1 (en) * 1998-12-15 2001-10-30 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
KR100801588B1 (ko) * 1999-09-21 2008-02-05 스키에파마 캐나다 인코포레이티드 생물학적 유효 물질의 표면 변형된 미립자 조성물
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
DE60137362D1 (de) * 2000-11-20 2009-02-26 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
AU2002322019A1 (en) * 2001-06-22 2003-01-08 Marie Lindner Method for high through put screening using a small scale mill or microfluidics
US7687053B2 (en) * 2001-08-20 2010-03-30 Boston Scientific Scimed, Inc. Embolic compositions with non-cyanoacrylate rheology modifying agents
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1429731B1 (en) * 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1429749A2 (en) 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP2005519657A (ja) * 2001-11-07 2005-07-07 インコール ファーマシューティカル カンパニー ナノ微粒子造影剤を用いた血管撮像の方法
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
ES2343405T3 (es) * 2002-02-04 2010-07-30 Elan Pharma International Ltd. Composiciones nanoparticuladas que tienen lisozima como un estabilizador de superficie.
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
JP2005526095A (ja) * 2002-03-20 2005-09-02 エラン ファーマ インターナショナル，リミティド 脆砕性の低い急速溶解投与剤型
WO2003082213A2 (en) * 2002-03-28 2003-10-09 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
WO2003086354A1 (en) 2002-04-12 2003-10-23 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
AU2003234452A1 (en) * 2002-05-06 2003-11-11 Elan Pharma International Ltd. Nanoparticulate nystatin formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2003241477A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
CA2492488A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
KR20060021278A (ko) * 2002-08-15 2006-03-07 윤킹 리우 고체 나노미터 의약 및 이의 제조방법
SI1553927T1 (sl) * 2002-09-11 2010-12-31 Elan Pharma Int Ltd Z gelom stabilizirani nanodeläśni sestavki uäśinkovine
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
WO2004043440A1 (en) * 2002-11-12 2004-05-27 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ES2431520T3 (es) 2003-01-25 2013-11-26 Seno Medical Instruments, Inc. Procedimiento de formación de imágenes optoacústicas de contraste elevado utilizando nanopartículas no esféricas
US7390505B2 (en) * 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) * 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
ES2318330T3 (es) * 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
ATE509618T1 (de) * 2003-11-05 2011-06-15 Elan Pharma Int Ltd Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
US7588751B2 (en) * 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
EP1776948B1 (en) * 2004-08-11 2015-12-09 Konica Minolta Medical & Graphic, Inc. Method of producing liposome-containing preparation
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
BRPI0519088A2 (pt) * 2004-12-15 2008-12-23 Elan Pharma Int Ltd formulaÇÕes de tacrolimo nanoparticuladas
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
MX2007008212A (es) * 2005-01-06 2007-08-16 Elan Pharma Int Ltd Formulaciones de candesartan en nanoparticulas.
KR20070112164A (ko) * 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
EA200701987A1 (ru) * 2005-03-16 2008-02-28 Элан Фарма Интернэшнл Лтд. Составы из нанодисперсного антагониста лейкотриеновых рецепторов/кортикостероида
EA200701997A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиция из наночастиц бисфосфоната
US8003127B2 (en) * 2005-03-23 2011-08-23 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof
MX2007012762A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
CA2604735A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
AU2006336417A1 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
EP1915139A1 (en) * 2005-05-16 2008-04-30 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising a cephalosporin
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
KR20080017067A (ko) * 2005-06-03 2008-02-25 엘란 파마 인터내셔널 리미티드 나노입자형 이마티닙 메실레이트 제제
JP2008542396A (ja) * 2005-06-03 2008-11-27 エラン ファーマ インターナショナル リミテッド ナノ粒子アセトアミノフェン製剤
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
AU2006259606A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
EP1931340A2 (en) * 2005-06-15 2008-06-18 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
KR20090015994A (ko) * 2006-05-30 2009-02-12 엘란 파마 인터내셔널 리미티드 나노입자형 포사코나졸 제제
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CA2695204A1 (en) * 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
US8901050B2 (en) 2010-03-31 2014-12-02 Chevron Oronite Company Llc Method for improving copper corrosion performance
US8933001B2 (en) 2010-03-31 2015-01-13 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
US9150811B2 (en) 2010-03-31 2015-10-06 Cherron Oronite Company LLC Method for improving copper corrosion performance
US8993496B2 (en) 2010-03-31 2015-03-31 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
US8716202B2 (en) 2010-12-14 2014-05-06 Chevron Oronite Company Llc Method for improving fluorocarbon elastomer seal compatibility
EP2873670A1 (en) 2013-11-14 2015-05-20 Bayer Pharma Aktiengesellschaft Bis azainositol zirconium complexes for X-ray imaging
CA2984421C (en) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
US4406878A (en) * 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DE4015741A1 (de) * 1990-05-16 1991-11-21 Metallgesellschaft Ag Verfahren zur herstellung von mg(pfeil abwaerts)2(pfeil abwaerts)si enthaltenden legierungen
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization

Also Published As

Publication number Publication date
PH30158A (en) 1997-01-21
FI935396A7 (fi) 1994-06-18
FI935396A0 (fi) 1993-12-02
IL107875A0 (en) 1994-04-12
HU9303490D0 (en) 1994-04-28
FI935396L (fi) 1994-06-18
US5326552A (en) 1994-07-05
CA2107165A1 (en) 1994-06-18
EP0602700A2 (en) 1994-06-22
NO934425D0 (no) 1993-12-06
NO934425L (no) 1994-06-20
NZ248727A (en) 1995-04-27
MY109875A (en) 1997-09-30
SK142793A3 (en) 1994-07-06
JPH06192131A (ja) 1994-07-12
MX9306012A (es) 1995-01-31
CZ266893A3 (en) 1994-08-17
AU664115B2 (en) 1995-11-02
KR940013544A (ko) 1994-07-15
EP0602700A3 (en) 1994-12-21
US5447710A (en) 1995-09-05
AU4867293A (en) 1994-06-30
HUT67265A (en) 1995-03-28

Similar Documents

Publication Publication Date Title
TW240171B (enEXAMPLES)
BR9304651A (enEXAMPLES)
AU632452B2 (enEXAMPLES)
AU2098792A (enEXAMPLES)
CN3015342S (enEXAMPLES)
AU1729392A (enEXAMPLES)
AU1045392A (enEXAMPLES)
AU1047592A (enEXAMPLES)
AU1052092A (enEXAMPLES)
AU1081792A (enEXAMPLES)
AU1098892A (enEXAMPLES)
AU1109992A (enEXAMPLES)
AU1117992A (enEXAMPLES)
AU1136092A (enEXAMPLES)
AU1281092A (enEXAMPLES)
AU1283492A (enEXAMPLES)
AU1299692A (enEXAMPLES)
AU1610792A (enEXAMPLES)
AU1622092A (enEXAMPLES)
AU1707592A (enEXAMPLES)
AU1708392A (enEXAMPLES)
CN3015444S (enEXAMPLES)
AU1813892A (enEXAMPLES)
AU1844392A (enEXAMPLES)
AU1849392A (enEXAMPLES)